natgillin/translations-raw huggingface dataset:
Patienterne skal rådes til ikke at køre bil eller betjene maskiner, hvis de oplever de nævnte symptomer, når de har fået Provenge- infusion.
Patients should be advised not to drive or use machines if they experience these symptoms following their infusion.
Patienterne skal sluge de filmovertrukne tabletter med vand.
Patients should swallow the film-coated tablets with water.
Patienterne skal straks underrette deres læge, hvis de har symptomer, der kan skyldes en infektion, såsom feber, ondt i halsen og influenzalignende symptomer.
Patients should tell their doctor immediately if they have symptoms that might be due to an infection, such as fever, sore throat and flu-like symptoms.
Patienterne skal sørge for, at kontrolvinduet har skiftet fra grøn til rød, hvilket angiver, at der er inhaleret korrekt (se billede 5).
Patients should check that the control window has turned to red from green, which indicates they have inhaled correctly (image 5).
Patienterne skal tage dabrafenib, som monoterapi eller i kombination med trametinib, mindst én time før eller mindst 2 timer efter et måltid på grund af mads indvirkning på absorptionen af dabrafenib (se pkt.
Patients should take dabrafenib as monotherapy or in combination with trametinib at least one hour prior to or two hours after a meal due to the effect of food on dabrafenib absorption (see section 5.2).
Patienterne skal under og efter infusionen overvåges for visse bivirkninger, og de skal have foretaget en komplet blodtælling før hver dosis af Adcetris.
Patients should be monitored during and after the infusion for certain side effects and they should have full blood counts checked before every dose of Adcetris.
Patienterne skal underrettes om, at det ikke er påvist, at tenofovirdisoproxilfumarat forebygger risikoen for overførsel af HBV til andre ved seksuel kontakt eller kontaminering af blod.
Patients must be advised that tenofovir disoproxil fumarate has not been proven to prevent the risk of transmission of HBV to others through sexual contact or contamination with blood.
Patienterne skal underrettes om, at under behandling med Myclausen kan vaccinationer være mindre effektive, og levende svækkede vacciner bør undgås (se pkt.
Patients should be advised that during treatment with Myclausen, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5).
Patienterne skal vaske hænder før og efter påsmøringer; det er ikke nødvendigt at bruge handsker.
Patients should wash their hands before and after applications; it is not necessary to wear gloves.
Patienterne skal vente i mindst 4 timer, før en ny episode med gennembrudssmerter behandles med PecFent.
Patients must wait at least 4 hours before treating another episode of BTP with PecFent.
Patienterne skal vise dette kort til deres partner eller plejer samt til andre læger, som behandler dem, da disse kan bemærke symptomer på PML, som patienten ikke selv er klar over, f.eks. ændret humør, adfærd eller tale.
Patients should show this card to their partner or carer, as well as to other doctors treating them, because they may notice symptoms of PML that the patient is not aware of, such as changes in mood, behaviour or speech.
Patienterne skal være i stabil behandling med en alfablokker før påbegyndelse af behandling med Spedra.
Patients should be stable on alpha-blocker therapy prior to initiating Spedra.
Patienterne skal være i stand til at overholde de krav, der stilles til sikker brug af pomalidomid
That patients should be capable of complying with the requirements for the safe use of pomalidomide
Patienterne skal være i stand til at overholde de krav, der stilles til sikker brug af Revlimid
That patients should be capable of complying with the requirements for the safe use of Revlimid
Patienterne skal være i stand til at overholde kravene til sikker brug af Opsumit;
That patients should be capable of complying with the requirements for the safe use of Opsumit;
Patienterne skal være klar over, at porfimer har en lang halveringstid, samt at stoffet aktiveres af lys.
Patients should be aware of the long half-life of porfimer and that the compound gets activated by light.
Patienterne skal være opmærksomme på situationer, hvor advarselssymptomerne på hypoglykæmi er nedsatte.
Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished.
Patienterne skal være opmærksomme på, hvordan de reagerer over for Adempas, før de fører motorkøretøj eller betjener maskiner.
Patients should be aware of how they react to this medicine, before driving or operating machines.
Patienterne skiftede behandling uden udvaskningsperiode.
Patients were switched without a washout period.
Patienterne skulle have en Karnofsky Performance-Score (KPS) 70%.
Patients had to have a Karnofsky Performance Score (KPS) 70%.
Patienterne skulle have forventet levetid ≥ 12 uger og måtte ikke tidligere have fået strålebehandling af bækken eller abdomen.
Patients should have had a life expectancy of  12 weeks and no prior radiotherapy to the pelvis or abdomen.
Patienterne skulle have hiv-1-RNA < 50 kopier/ml og CD4-celletal > 300 celler/mm3 ved screening.
Patients were required to have an HIV-1 RNA < 50 copies/ml and CD4 count > 300 cells/mm3 at screening.
Patienterne skulle have hvert af lægemidlerne så længe, de kunne, indtil deres sygdom forværredes, eller indtil behandlingen af dem blev for giftig for dem.
Patients were to receive either medicine for as long as they could until their disease got worse or their treatment became too toxic for them.
Patienterne skulle have sygdomsprogression inden for 6 måneder af deres sidste kemoterapi-kur.
Patients must have progressed within 6 months of their last chemotherapeutic regimen.
Patienterne skulle have været stabilt supprimerede (hiv 1-rna < 50 kopier/ml) i mindst 6 måneder før screening.
Patients had to have been stably suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months prior to screening.
Patienterne skulle inden inklusion have verificeret CD20+ CLL samt opfylde én eller begge af følgende mål for andre samtidige sygdomme: en co-morbiditetsscore (CIRS) på mere end 6 eller nedsat nyrefunktion svarende til CrCl <70 ml/min.
Prior to enrolment, patients had to have documented CD20+ CLL, and one or both of the following measures of coexisting medical conditions: comorbidity score (CIRS) of greater than 6 or reduced renal function as measured by CrCl <70 mL/min.
Patienterne skulle også være uegnede til intensiv kemoterapi og/eller transplantation på tidspunktet for inklusion i studiet.
Also, patients had to be ineligible for intensive chemotherapy and/or transplant at time of inclusion in the study.
Patienterne skulle være behandlingsnaive med hensyn til tenofovirdisoproxilfumarat, men kunne have fået interferon-baserede regimer (> 6 måneder før screening) eller anden anti-HBV nukleosid/nukleotid-behandling (> 16 uger før screening), der ikke indeholdt tenofovirdisoproxilfumarat.
Subjects must have been naïve to tenofovir disoproxil fumarate, but could have received interferon based regimens (> 6 months prior to screening) or any other non-tenofovir disoproxil fumarate containing oral anti-HBV nucleoside/nucleotide therapy (> 16 weeks prior to screening).
Patienterne skulle være på enten deres første eller andet antiretrovirale program uden virologisk svigt i anamnesen, have en anamnese uden nuværende eller tidligere resistens over for nogen af de tre stoffer i Eviplera og være stabilt supprimerede (hiv 1- rna < 50 kopier/ml) i mindst 6 måneder inden screening.
Patients had to be on either their first or second antiretroviral regimen with no history of virologic failure, have no current or past history of resistance to any of the three components of Eviplera, and must have been stably suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months prior to screening.
Patienterne var 3-17 år gamle med et aktivt polyartikulært forløb af børnegigt (JRA) uanset starttype og ikke forud testet overfor methotrexat eller leflunomid.
3-17 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide.
Patienterne var 3-17 år gamle med et aktivt polyartikulært forløb af børnegigt (JRA) uanset starttype og ikke forud testet overfor methotrexat eller leflunomid.
Patients were 3–17 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide.
Patienterne var 3-17 år gamle med et aktivt polyartikulært forløb af børnegigt (JRA) uanset starttype og ikke forud testet overfor methotrexat eller leflunomide.
3-17 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide.
Patienterne var 3-17 år gamle med et aktivt polyartikulært forløb af børnegigt (JRA) uanset starttype og ikke forud testet overfor methotrexat eller leflunomide.
Patients were 3–17 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide.
Patienterne var blevet behandlet tidligere, men enten havde behandlingerne ikke virket, eller også var sygdommen vendt tilbage.
The patients had previously been treated but the treatments had not worked or the disease had come back.
Patienterne var diagnosticeret med kronisk ITP i mindst 1 år og havde refraktær sygdom eller recidiv efter mindst én tidligere ITP-behandling eller var ikke i stand til at fortsætte med andre ITP-behandlinger af en medicinsk årsag og havde trombocyttal <30.000/µl.
Subjects were diagnosed with chronic ITP for at least 1 year and were refractory or relapsed to at least one prior ITP therapy or unable to continue other ITP treatments for a medical reason and had platelet count < 30,000/µl.
Patienterne var egnede til at deltage, hvis de var 50 år eller derover, tidligere havde haft MI (1 til 3 år før randomisering) og havde mindst én af følgende risikofaktorer for aterotrombose: alder ≥65 år, diabetes mellitus med behov for medicin, et andet tidligere MI, evidens for multikar-CAD eller kronisk nedsat nyrefunktion, der ikke er i slutstadiet.
Patients were eligible to participate if they were aged 50 years or over, with a history of MI (1 to 3 years prior to randomisation), and had at least one of the following risk factors for atherothrombosis: age ≥65 years, diabetes mellitus requiring medication, a second prior MI, evidence of multivessel CAD, or chronic non-end-stage renal dysfunction.
Patienterne var enten behandlingsnaive (50 %) eller forbehandlede med en endothelin-receptorantagonist (ERA, 43 %) eller en prostacyklinanalog (inhaleret (iloprost), oral (beraprost) eller subkutan (treprostinil) 7 %), og er blevet diagnosticeret med idiopatisk eller arvelig PAH (63,4 %), PAH forbundet med bindevævssygdom (25,1 %) og medfødt hjertesygdom (7,9 %).
Patients were either treatment-naïve (50%) or pre-treated with an endothelin receptor antagonist (ERA; 43%) or a prostacyclin analogue (inhaled (iloprost), oral (beraprost) or subcutaneous (treprostinil); 7%) and had been diagnosed with idiopathic or heritable PAH (63.4%), PAH associated with connective tissue disease (25.1%) and congenital heart disease (7.9%).
Patienterne var enten naïve for Herceptin i.v.-behandling (20,3 %) eller havde tidligere fået Herceptin i.v. (79,7 %).
Patients were either naïve to Herceptin IV treatment (20.3%) or pre- exposed to Herceptin IV (79.7%).
Patienterne var i behandling i ni eller 14 uger.
The patients were treated for nine or 14 weeks.
Patienterne var i forvejen blevet behandlet med desmopressin eller von Willebrand-faktor og havde, i den første del af undersøgelsen, fået Voncento i 12 måneder.
The patients had previously been treated with desmopressin or von Willebrand factor and, in the first part of the study, received Voncento for 12 months.
Patienterne var i WHO- funktionsklasse I (n=19 patienter, 29%), II (n=27 patienter, 42%) eller III (n=18 patienter, 28%) ved opstart af studiebehandlingen.
Patients were in WHO functional class I (n = 19 patients, 29 %), class II (n = 27 patients, 42%) or class III (n = 18 patients, 28%) at start of study treatment.
Patienterne var i WHO-funktionsklasse I (n=19 patienter, 29%), II (n=27 patienter, 42%) eller III (n=18 patienter, 28%) ved opstart af studiebehandlingen.
Patients were in WHO functional class I (n = 19 patients, 29 %), class II (n = 27 patients, 42%) or class III (n = 18 patients, 28%) at start of study treatment.
Patienterne var mellem 18 og 70 år gamle og havde aktiv prosiasis artrit ( 3 svulne led og  3 ømme led) i mindst en af følgende former: (1) i distale interfalangeale led, (2) polyartikulær artrit (ingen reumatoide knuder og tilstedeværelse af psoriasis), (3) arthritis mutilans, (4) asymetrisk psoriasisartrit eller (5) spondylitis-lignende ankylose.
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis- like ankylosis.
Patienterne var mellem 18 og 70 år gamle og havde aktiv prosiasis artrit ( 3 svulne led og  3 ømme led) i mindst en af følgende former: (1) i distale interfalangeale led, (2) polyartikulær artrit (ingen reumatoide knuder og tilstedeværelse af psoriasis), (3) arthritis mutilans, (4) asymetrisk psoriasisartrit eller (5) spondylitis-lignende ankylose.
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like ankylosis.
Patienterne var mellem 18 og 70 år gamle og havde aktiv psoriasisartrit ( 3 svulne led og  3 ømme led) i mindst en af følgende former: (1) i distale interfalangeale led, (2) polyartikulær artrit (ingen reumatoide knuder og tilstedeværelse af psoriasis), (3) arthritis mutilans, (4) asymetrisk psoriasisartrit eller (5) spondylitis-lignende ankylose.
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like ankylosis.
Patienterne var mellem 18 og 70 år og havde aktiv psoriasisartrit (≥ 3 hævede led og ≥ 3 ømme led) i mindst en af følgende former: (1) i distale interfalangeale led, (2) polyartikulær artrit (ingen reumatoide knuder og tilstedeværelse af psoriasis), (3) arthritis mutilans, (4) asymmetrisk psoriasisartrit eller (5) spondylitis-lignende ankylose.
Patients were between 18 and 70 years of age and had active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis- like ankylosis.
Patienterne var stratificeret udfra region, undergruppe af indolent non-Hodgkin lymfom (follikulært versus ikke-follikulært), rituximab-refraktær type (hvorvidt patienten var refraktær over for tidligere rituximab monoterapi eller rituximab i kombination med kemoterapi) samt antallet af tidligere behandlinger (≤ 2 versus > 2).
Patients were stratified according to region, iNHL subtype (follicular versus non-follicular), rituximab-refractory type (whether refractory to prior rituximab monotherapy or rituximab in combination with chemotherapy) and the number of prior therapies (≤2 versus >2).
Patienterne var uegnede, hvis der var planlagt anvendelse af en P2Y12-receptorantagonist, dipyridamol, cilostazol eller behandling med antikoagulantia under studiet; hvis de havde en blødningsforstyrrelse eller tidligere iskæmisk apopleksi eller intrakraniel blødning, en tumor i centralnervesystemet eller en intrakraniel vaskulær abnormitet; hvis de havde haft gastrointestinal blødning inden for de foregående 6 måneder eller gennemgået større operationer inden for de foregående 30 dage.
Patients were ineligible if there was planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period; if they had a bleeding disorder or a history of an ischaemic stroke or intracranial bleeding, a central nervous system tumour, or an intracranial vascular abnormality; if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days.
Patienterne var ≥ 18 år.
≥ 10% of the body surface area who were ≥ 18 years old.
Patienterne vil ligeledes få et patientinformationskort fra deres læge, som indeholder et sammendrag af vigtige sikkerhedsoplysninger om lægemidlet.
Patients will also receive from their doctor an alert card summarising key safety information on the medicine.
Patienterne vil ligeledes modtage et patientinformationskort med de vigtigste oplysninger om sikkerhed i forbindelse med lægemidlet.
Patients will also receive an alert card summarising key safety information on the medicine.
Patienterne, der blev tildelt Herceptin, fik en initial støddosis på 8 mg/kg efterfulgt af 6 mg/kg hver 3. uge i enten et eller to år.
Patients assigned to receive Herceptin were given an initial loading dose of 8 mg/kg, followed by 6 mg/kg every three weeks for either one or two years.
Patienterne, der oplevede symptomer på CNS-depression, typisk midlertidig koma eller lavt bevidsthedsniveau, letargi, somnolens, hypotoni, bradykardi, hypotermi, bleghed, vejrtrækningsbesvær og apnø og behov for indlæggelse på intensiv afdeling, hvor intubation er indiceret.
The subjects experienced symptoms of CNS depression, typically temporary coma or low level of consciousness, lethargy, somnolence, hypotonia, bradycardia, hypothermia, pallor, respiratory depression and apnoea, and required admission to intensive care with intubation if indicated.
Patienterne, som fik 5 mg Volibris én gang dagligt, kunne i gennemsnit gå 36 m længere efter 12 ugers behandling, mens patienterne, der fik placebo, kunne gå 9 m mindre.
The patients taking 5 mg Volibris once a day could walk an average of 36 m more after 12 weeks of treatment, while the patients taking placebo could walk 9 m less.
Patienterne, som fik den lavere dosis Torisel i kombination med interferon alfa, overlevede lige så længe (8,4 måneder) som dem, der fik interferon alfa alene.
The patients receiving the lower dose of Torisel in combination with interferon alfa survived for a similar length of time (8.4 months) as those taking interferon alfa alone.
Patienterne, som ikke opnåede det tildelte PASI-respons efter uge 32, eller som indledningsvist blev randomiseret til placebo, blev i behandling med apremilast indtil uge 52.
Patients who did not achieve the designated PASI response by Week 32, or who were initially randomized to placebo, remained on apremilast until Week 52.
Patienternes alder varierede fra 25 til 72 år.
The age of these patients ranged from 25 to 72years.
Patienternes ansvar i forhold til insulinbehandling samt frekens for genopfyldning og vedligeholdelse af pumpen som beskrevet i nøglebeskederne i indlægssedlen;
Patients’ responsibilities regarding insulin treatment as well as refill frequency and maintenance of the pump as outlined in the key messages in the patient information leaflet;
Patienternes demografi og sygdomskarakteristika ved baseline var generelt velbalanceret mellem armene: Medianalderen var 62 år, 67 % af patienterne var mænd, 82 % var kaukasiere, 13 % asiater; ECOG-PS var 0 for 32 % af patienterne og 1 for 67 % af patienterne, 73 % af patienterne havde ikke- planocellulær histologi, og 26 % havde planocellulær histologi.
Baseline patient demographics and disease characteristics were generally balanced between arms: the median age was 62 years; 67% of patients were male; 82% were Caucasian, 13% Asian; the ECOG PS was 0 for 32% of patients, 1 for 67% of patients; 73% of patients had non-squamous histology and 26% had squamous histology.
Patienternes demografiske karakteristika og baseline- sygdomskarakteristika var velafbalanceret mellem behandlingsgrupperne, og der blev ikke fundet statistisk signifikante forskelle.
Patient demographics and baseline disease characteristics were well balanced between the treatment groups, and no statistically significant differences were noted.
Patienternes egen rapportering af symptomer ved brug af ublindede vurderinger viste en klar tendens til symptomforbedring med oral topotecan + BSC.
Patient self-reports of symptoms using an unblinded assessment showed a consistent trend for symptom benefit for oral topotecan + BSC.
Patienternes gennemsnitlige HbA1c før behandlingen var mellem 7,6 og 8,5 %, og behandlingen varede i mindst 52 uger.
The patients’ average HbA1c at baseline ranged from 7.6 to 8.5% and patients were treated for at least 52 weeks.
Patienternes globale vurdering af smertelindringsmetode – første 24 timer (% patienter med vurderingen god eller meget god)
Patient Global Assessment of Method of Pain Control -1st 24 hour (% of patients rating good or excellent)
Patienternes HbA1c-niveau faldt fra et baseline-niveau på over 7,5 % til mellem 1,22 og 1,64 %.
The patients’ HbA1c levels fell from a baseline of over 7.5% by between 1.22 and 1.64%.
Patienternes HER2- receptorstatus blev bestemt retrospektivt på centrallaboratoriet.
HER2 receptor status was retrospectively determined by central laboratory testing.
Patienternes hydreringsstatus skal vurderes før og efter administrationen af Zoledronsyre medac for at sikre, de er tilstrækkeligt hydrerede.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid medac to assure that they are adequately hydrated.
Patienternes hydreringsstatus skal vurderes før og efter indgivelsen af zoledronsyre for at sikre, de er tilstrækkeligt hydrerede.
The hydration status of patients must be assessed prior to and following administration of zoledronic acid to ensure that they are adequately hydrated.
Patienternes hydreringsstatus skal vurderes før og efter indgivelsen af Zoledronsyre Teva for at sikre, de er tilstrækkeligt hydrerede.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid Teva to assure that they are adequately hydrated.
Patienternes hydreringsstatus skal vurderes før og efter indgivelsen af Zometa for at sikre, de er tilstrækkeligt hydrerede.
The hydration status of patients must be assessed prior to and following administration of Zometa to assure that they are adequately hydrated.
Patienternes indhold af LDL- kolesterol faldt i gennemsnit med 40 %.
On average, the patients’ LDL cholesterol levels were reduced by 40%.
Patienternes kliniske status, sociale situation og alkoholforbrugsmønter blev evalueret ved det første besøg (baseret på patientens egne oplysninger).
At the initial visit, the patients’ clinical status, social situation, and alcohol consumption pattern were evaluated (based on patient reporting).
Patienternes knoglemarv indeholdt op til 30 % abnorme celler.
The patients’ bone marrow contained up to 30% abnormal cells.
Patienternes medianalder var 61,0 år (spændevidde 25-84).
The median age of patients was 61.0 (range: 2584) years.
Patienternes mediane LVEF ved baseline var 65,0 % (interval 50 % - 88 %) for begge grupper.
Patients’ median LVEF at baseline was 65.0% (range 50% – 88%) in both groups.
Patienternes respons bør overvåges, når de skiftes fra samtidige ikke-inducerende antiepileptika til enzyminducerende lægemidler og omvendt.
Patients’ response should be monitored when they are switching from concomitant non-inducer anti-epileptic medicinal products to enzyme inducing medicinal products and vice versa.